GAM Holding AG Reduces Holdings in DexCom, Inc. (NASDAQ:DXCM)

GAM Holding AG reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 71.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,530 shares of the medical device company’s stock after selling 23,609 shares during the period. GAM Holding AG’s holdings in DexCom were worth $741,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Creative Planning raised its stake in DexCom by 22.3% during the third quarter. Creative Planning now owns 59,573 shares of the medical device company’s stock valued at $3,994,000 after buying an additional 10,880 shares in the last quarter. Blue Trust Inc. grew its holdings in DexCom by 101.9% in the 3rd quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after buying an additional 898 shares in the last quarter. Private Advisor Group LLC grew its stake in shares of DexCom by 5.7% in the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock worth $759,000 after purchasing an additional 608 shares in the last quarter. Aquila Investment Management LLC lifted its holdings in DexCom by 50.0% in the third quarter. Aquila Investment Management LLC now owns 42,000 shares of the medical device company’s stock worth $2,816,000 after purchasing an additional 14,000 shares during the period. Finally, Lecap Asset Management Ltd. grew its position in DexCom by 90.8% in the 3rd quarter. Lecap Asset Management Ltd. now owns 47,543 shares of the medical device company’s stock valued at $3,187,000 after buying an additional 22,623 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on DXCM shares. Citigroup increased their price objective on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Oppenheimer cut their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, Wells Fargo & Company boosted their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.06.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,083 shares of company stock worth $3,309,794. Corporate insiders own 0.30% of the company’s stock.

DexCom Trading Up 1.6 %

Shares of DXCM stock opened at $90.53 on Wednesday. The company has a market cap of $35.36 billion, a PE ratio of 54.21, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The business’s 50 day moving average is $82.65 and its two-hundred day moving average is $75.62.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. Equities analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.